Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride (KCl) provides potassium ions, essential for maintaining intracellular fluid volume, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose 5% provides water and calories for energy, correcting fluid deficits and dehydration. Sodium chloride 0.3% provides sodium and chloride ions to maintain extracellular fluid osmolarity and volume. The combination corrects electrolyte imbalances and provides maintenance fluids.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion, rate determined by potassium deficit and serum potassium monitoring; typical maintenance: 20-40 mEq potassium per day in divided doses; maximum infusion rate: 10 mEq/h; maximum concentration: 40 mEq/L via peripheral line.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium does not have a classic terminal half-life as it is an electrolyte; its clearance depends on body distribution and renal function. In patients with normal renal function, the elimination half-life for an administered dose is approximately 3–6 hours, reflecting distribution into intracellular space and subsequent renal excretion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: ~90% of potassium is excreted by the kidneys, primarily via distal tubular secretion under aldosterone regulation; ~10% is lost in feces via colonic secretion. Biliary excretion is negligible. In this formulation, dextrose and sodium chloride are also excreted renally.
Category C
Category A/B
Electrolyte
Electrolyte